Bártulos Iglesias M, Marzo Sola M E, Estrella Ruiz L A, Bravo Anguiano Y
Asociación de Esclerosis Múltiple de La Rioja, Logroño, La Rioja, España; Sección de Neurología, Hospital Universitario de Burgos, Burgos, España.
Sección de Neurología, Hospital San Pedro , Logroño, La Rioja, España.
Neurologia. 2015 Nov-Dec;30(9):552-60. doi: 10.1016/j.nrl.2014.04.016. Epub 2014 Jun 26.
Multiple sclerosis is a demyelinating disease that causes severe disability in younger patients. Many epidemiology studies have confirmed a variable prevalence. The objective of this study was to analyse the prevalence of this disease in La Rioja (Spain), using such variables as age and sex; type of progression, initial form of the disease, EDSS and number of relapses; disease-modifying treatment and reasons for treatment withdrawal; personal and family history of cancer; and incidence and mortality.
Analysis of patients in La Rioja diagnosed with MS (according to Poser criteria or the 2005 McDonald criteria) during a 10-year period (2001-2011). Data were collected from hospital records, multiple sclerosis associations, and personal records kept by neurologists.
The MS prevalence rate in La Rioja is 65 patients/100 000 inhabitants with an incidence rate of 3.5 cases/100 000 residents per year. Relapsing-remitting MS is present in 67.6% of the patient total. Mean age of onset is 20-29 years (range, 12 to 70). Most EDSS scores were mostly ≤ 2. Untreated MS cases account for 47.6% of the total and the most commonly used therapy is interferon. We detected 4 haematological tumours and 7 families with multiple members affected by MS.
Prevalence and incidence are similar to those found in other regions Spain. The average age at onset age for primary progressive MS is slightly higher than in other papers (40-49 years). In families with multiple patients, MS may be more aggressive. Disability in these patients remains very severe. We require more epidemiology studies with a variety of data gathering methods to support findings for prevalence obtained in different provinces.
多发性硬化症是一种脱髓鞘疾病，会导致年轻患者严重残疾。许多流行病学研究已证实其患病率存在差异。本研究的目的是分析西班牙拉里奥哈地区这种疾病的患病率，并使用年龄、性别、疾病进展类型、疾病初始形式、扩展残疾状态量表（EDSS）和复发次数、疾病修饰治疗及治疗中断原因、个人和家族癌症病史以及发病率和死亡率等变量进行分析。
对拉里奥哈地区在10年期间（2001 - 2011年）被诊断为多发性硬化症（根据波泽标准或2005年麦克唐纳标准）的患者进行分析。数据收集自医院记录、多发性硬化症协会以及神经科医生保存的个人记录。
拉里奥哈地区多发性硬化症的患病率为每10万居民中有65例患者，发病率为每年每10万居民中有3.5例。复发缓解型多发性硬化症占患者总数的67.6%。平均发病年龄为20 - 29岁（范围为12至70岁）。大多数EDSS评分大多≤2。未治疗的多发性硬化症病例占总数的47.6%，最常用的治疗方法是干扰素。我们检测到4例血液系统肿瘤以及7个有多名成员患多发性硬化症的家庭。
患病率和发病率与西班牙其他地区相似。原发进展型多发性硬化症的平均发病年龄略高于其他研究报告（40 - 49岁）。在有多名患者的家庭中，多发性硬化症可能更具侵袭性。这些患者的残疾程度仍然非常严重。我们需要更多采用多种数据收集方法的流行病学研究来支持不同省份获得的患病率研究结果。
